Board Meeting5 May 2026, 06:11 pm
Sandu Pharma Recommends ₹1 Dividend, Appoints Cost Auditor
AI Summary
Sandu Pharmaceuticals Ltd's board meeting on May 5, 2026, approved standalone audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1 per equity share (10% on paid-up capital) subject to shareholder approval. M/s Shekhar Joshi & Co was appointed as the Cost Auditor for FY 2026-27. Additionally, M/S Akhil Pai & Co and M/S Uday & Uday Associates were appointed as internal auditors for Goa and Mumbai plants, respectively.
Key Highlights
- Standalone audited financial results for FY26 approved by the board.
- Final dividend of ₹1 per share recommended, pending shareholder approval.
- M/s Shekhar Joshi & Co appointed as Cost Auditor for FY 2026-27.
- Internal Auditors appointed for Goa and Mumbai plants.
- Statement of Utilizations and Deviations noted as per SEBI regulations.
Price Impact
More from SANDUPHQ